SCHEMBL4076934

SCHEMBL4076934

[CH2]C(c1ccccc1)c1ccncc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 4/20 0.68
SLC6A2 P23975 3/20 0.68
SLC6A4 P31645 3/20 0.68
NOTUM Q6P988 1/20 0.48
GAA P10253 1/20 0.47
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 2/20 0.44
POLB P06746 1/20 0.44
MAPT P10636 1/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CFTR P13569 1/20 0.43
GOPC Q9HD26 1/20 0.43
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
CYP19A1 P11511 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8463112 0.92 SLC6A2 (0.55) SLC6A3SLC6A2SLC6A4NOTUMGAA
SCHEMBL38016 0.83 DPP4 (0.50) SLC6A3SLC6A2SLC6A4
SCHEMBL733008 0.81 SLC6A3 (1.00) SLC6A3SLC6A2SLC6A4NOTUMGAA
SCHEMBL28167953 0.80 DPP4 (0.47) SLC6A3SLC6A2SLC6A4
SCHEMBL27991580 0.80 DPP4 (0.47) SLC6A3SLC6A2SLC6A4
SCHEMBL28995862 0.80 DPP4 (0.47) SLC6A3SLC6A2SLC6A4
SCHEMBL6650027 0.80 SLC6A3 (0.56) SLC6A3SLC6A2SLC6A4NOTUMGAA
SCHEMBL6508386 0.80 SLC6A2 (0.45) SLC6A3SLC6A2SLC6A4GAAKMT2A
Ammonia Solution, Strong SCHEMBL5999715 0.79 SLC6A3 (0.95) SLC6A3SLC6A2SLC6A4NOTUMGAA
SCHEMBL4067517 0.78 CFTR (0.65) SLC6A3SLC6A2SLC6A4GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100572381-C Pyrazolonaphthyridine derivative ASKA PHARM CO LTD (JP) 2009-12-23 CN disclosed
EP-1415986-B1 SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS BANYU PHARMA CO LTD (JP) 2009-04-08 EP disclosed
US-7205417-B2 Spiro compounds BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-04-17 US disclosed
EP-1501807-A1 SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS Elan Pharmaceuticals, Inc. (US) 2005-02-02 EP disclosed
CN-1538956-A Spiro compounds ������ҩ��ʽ���� 2004-10-20 CN disclosed
WO-2003093245-A1 SULFONYLQUINOXALONE ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ ANTAGONISTS ELAN PHARMACEUTICALS, INC. (US) 2003-11-13 WO disclosed
US-5622953-A DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG BASF AKTIENGESELLSCHAFT (DE) 1997-04-22 US disclosed
EP-0691962-A1 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE BASF AKTIENGESELLSCHAFT (DE) 1996-01-17 EP disclosed
US-5405843-A Anticancer drug potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1995-04-11 US disclosed
EP-0363212-B1 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS (JP) 1995-01-04 EP disclosed
WO-1994022842-A1 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE BASF AKTIENGESELLSCHAFT (DE) 1994-10-13 WO disclosed
US-5204348-A Quinoline derivatives MITSUI TOATSU CHEMICALS INC. (JP) 1993-04-20 US disclosed
US-5112817-A Anticancer Drug Potentiators MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1992-05-12 US disclosed
EP-0363212-A2 Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components MITSUI TOATSU CHEMICALS, Inc. (JP) 1990-04-11 EP disclosed